Read More Healthcare Industry News Hikma secures exclusive rights to $436M cancer drug in deal with Novugen Find out how Hikma is strengthening its US oncology portfolio with exclusive rights to a $436M cancer treatment. byPallavi MadhirajuApril 19, 2025